KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Income from Continuing Operations (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Income from Continuing Operations data on record, last reported at 229393000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 118.44% year-over-year to 229393000.0; the TTM value through Dec 2025 reached 381387000.0, up 16.1%, while the annual FY2025 figure was 381387000.0, 16.09% up from the prior year.
  • Income from Continuing Operations reached 229393000.0 in Q4 2025 per IONS's latest filing, down from 128607000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 325419000.0 in Q4 2023 and bottomed at 229393000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 56800200.0, with a median of 87553000.0 recorded in 2021.
  • The widest YoY moves for Income from Continuing Operations: up 720.24% in 2023, down 213.69% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 254533000.0 in 2021, then crashed by 120.61% to 52467000.0 in 2022, then soared by 720.24% to 325419000.0 in 2023, then tumbled by 132.27% to 105012000.0 in 2024, then tumbled by 118.44% to 229393000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 229393000.0 in Q4 2025, 128607000.0 in Q3 2025, and 123551000.0 in Q2 2025.